This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...


1 Thane Road West, Beeston, Nottingham, NG2 3AA
Telephone: +44 (0)1159 595 165
Fax: +44 (0)1159 592 565

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 28/02/2013
SPC Boots Dry Cough Relief 2.5 mg Lozenges

Go to top of the page
1. Name of the medicinal product

Boots Dry Cough Relief 2.5mg Lozenges

Go to top of the page
2. Qualitative and quantitative composition

Active ingredient


Dextromethorphan Hydrobromide BP


Go to top of the page
3. Pharmaceutical form


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Cough suppressant for the relief of acute non-productive (dry, tickly) cough associated with respiratory tract infection.

For oral administration.

Go to top of the page
4.2 Posology and method of administration

Adults and children over 12 years: A lozenge should be sucked whenever the cough is troublesome. Not more than 10 lozenges should be taken in one day.

The normal adult dose is still appropriate in the elderly.

Children 6 to 12 years: Not more than 2 lozenges within any 4 hours, and not more than 7 in any one day.

This medicine is contraindicated in children under 6 years of age (see section 4.3).

Children of 6-12 years of age: not to be used for more than 5 days without the advice of a doctor. Parents or carers should seek medical attention if the child's condition deteriorates during treatment.

Warning: Do not exceed the stated dose.

Keep all medicines out of the sight and reach of children.

Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substance or any of the excipients.

Dextromethorphan should not be given to subjects in, or at risk of developing respiratory failure.

Should not be taken by patients with liver disease.

Patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment (see also section 4.5).

Patients taking selective serotonin reuptake inhibitors (SSRI's, see section 4.5).

Not to be used in children under the age of 6 years.

Go to top of the page
4.4 Special warnings and precautions for use

Should be used with caution in atopic children due to histamine release.

Ask a doctor before use if you suffer from a chronic or persistent cough, if you have asthma or are suffering from an acute asthma attack or where cough is accompanied by excessive secretions.

Do not take with any other cough and cold medicine.

Use of dextromethorphan with alcohol or other CNS depressants may increase the effects on the CNS and cause toxicity in relatively smaller doses.

If symptoms do not go away talk to your doctor.

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Not to be used in patients taking monoamine oxidase inhibitors or within 14 days of stopping treatment as there is a risk of serotonin syndrome (pyrexia, hypertension, arrhythmias) when MAOIs are taken in combination with dextromethorphan.

(Severe and sometimes fatal reactions have been reported following administration of dextromethorphan to patients receiving MAOIs (see also section 4.3)).

Dextromethorphan is primarily metabolised by the cytochrome P450 isoenzyme CYP2D6; the possibility of interactions with inhibitors of this enzyme, including amiodarone, haloperidol, propafenone, quinidine, SRRIs, and thioridazine, should be borne in mind.

Dextromethorphan might exhibit additive CNS depressant effects when co-administered with alcohol, antihistamines, psychotropics, and other CNS depressant drugs.

Go to top of the page
4.6 Pregnancy and lactation

There is no or inadequate evidence of the safety of dextromethorphan in human pregnancy and therefore the lozenges should not be used during this period. No information is available on the secretion of dextromethorphan into breast milk and it is recommended that the product should not be used by breast feeding mothers.

Go to top of the page
4.7 Effects on ability to drive and use machines

No adverse effects known.

Go to top of the page
4.8 Undesirable effects

The following side effects may be associated with the use of dextromethorphan; Occasional drowsiness, dizziness, excitation, mental confusion, convulsions, respiratory depression, vomiting, gastrointestinal disturbances (nausea and diarrhoea) and skin reactions including rash.

Go to top of the page
4.9 Overdose

It is thought to be of low toxicity, but the effects in overdosage will be potentiated by simultaneous ingestion of alcohol and psychotropic drugs.

Symptoms: These include nausea and vomiting, CNS depression, dizziness, dysarthria (slurred speech), nystagmus, somnolence (drowsiness), excitation, mental confusion, psychotic disorder (psychosis), and respiratory depression. Other effects may include: abdominal discomfort, hallucinations, hypotension and ataxia.

Management: Treatment of overdose should be symptomatic and supportive. Gastric lavage may be of use. In severe overdosage the specific narcotic antagonist naloxone may be given.

Information regarding children aged 6-12 years :

Naloxone has been used successfully to reverse central or peripheral opioid effects of dextromethorphan in children (0.01mg/kg body weight).

Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Dextromethorphan is a cough suppressant.

Go to top of the page
5.2 Pharmacokinetic properties

Dextromethorphan is well-absorbed from the gastrointestinal tract, metabolised in the liver and excreted as both unchanged drug and demethylated metabolites.

Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.

Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Star anise oil

Strong capsicum tincture


Natural blackcurrant flavour 3109382


Sugar/glucose liquid sugar

Go to top of the page
6.2 Incompatibilities

None stated.

Go to top of the page
6.3 Shelf life

24 months.

Go to top of the page
6.4 Special precautions for storage

Do not store above 30°C.

Go to top of the page
6.5 Nature and contents of container

A card carton containing two blister push-through packs consisting of PVC/PVDC blisters heat sealed to hard temper aluminium foil. There are 12 lozenges on each blister and two trays in each carton.

Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.

Go to top of the page
7. Marketing authorisation holder

The Boots Company PLC

1 Thane Road West

Nottingham NG2 3AA

Go to top of the page
8. Marketing authorisation number(s)

PL 00014/0357

Go to top of the page
9. Date of first authorisation/renewal of the authorisation

Date of first authorisation:

20 January 1988

Date of last renewal:

20 January 2003

Go to top of the page
10. Date of revision of the text

February 2013

More information about this product

Link to this document from your website:

Active Ingredients/Generics